Universal Scientific Industrial (Shanghai) (601231) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue was RMB 16.43 billion, down 1.16% year-over-year; net profit attributable to shareholders rose 21.98% to RMB 625 million for the quarter.

• For January–September 2025, revenue was RMB 43.64 billion, down 0.83% year-over-year; net profit attributable to shareholders was RMB 1.26 billion, down 2.6% year-over-year.

• Total profit in Q3 2025 increased 30.45% year-over-year, mainly due to lower net foreign exchange losses and investment income from the sale of equity in a subsidiary.

Financial highlights

• Q3 2025 basic EPS was RMB 0.29, up 26.09% year-over-year; diluted EPS was RMB 0.28, up 21.74%.

• Net cash flows from operating activities for January–September 2025 were RMB 1.83 billion, down 8.66% year-over-year.

• Total assets as of September 30, 2025, were RMB 42.14 billion, up 5.36% from December 31, 2024.

• Owners' equity attributable to shareholders was RMB 18.93 billion, up 5.53% from year-end 2024.

Outlook and guidance

• Q4 2025 revenue is expected to be similar to the same period last year, with operating profit margin remaining stable year-over-year.

• Guidance is subject to uncertainties including global pandemic trends, international trade stability, and industry conditions.